Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation receiving long-term treatment:: A population analysis by nonlinear mixed effect modeling.

被引：0

作者：

Grind, M ^{[1
]}

Hamrén, B ^{[1
]}

Bååthe, S ^{[1
]}

Wollbratt, M ^{[1
]}

Eriksson, UG ^{[1
]}

机构：

[1] AstraZeneca, Loughborough, Leics, England

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：P31 / P31

页数：1

共 50 条

[1] Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy
Bååthe S.
Hamrén B.
Karlsson M.O.
Wollbratt M.
Grind M.
Eriksson U.G.
[J]. Clinical Pharmacokinetics, 2006, 45 (8) : 803 - 819
[2] Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy
Baathe, Sofie
Hamren, Bengt
Karlsson, Mats O.
Wollbratt, Maria
Grind, Margaretha
Eriksson, Ulf G.
[J]. CLINICAL PHARMACOKINETICS, 2006, 45 (08) : 803 - 819
[3] Ximelagatran: a long-term oral direct thrombin inhibitor for stroke and systemic embolism prevention in nonvalvular atrial fibrillation patients
Olsson, SB
Petersen, P
[J]. EUROPEAN HEART JOURNAL, 2002, 23 : 239 - 239
[4] Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects
Wolzt, M
Wollbratt, M
Svensson, M
Wåhlander, K
Grind, M
Eriksson, UG
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (07) : 537 - 543
[5] Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects
Michael Wolzt
Maria Wollbratt
Mia Svensson
Karin Wåhlander
Margaretha Grind
Ulf G. Eriksson
[J]. European Journal of Clinical Pharmacology, 2003, 59 : 537 - 543
[6] Comparison of the pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor, in patients with nonvalvular atrial fibrillation and elderly healthy subjects.
Eriksson, UG
Wollbratt, M
Wolzt, M
Svensson, M
Grind, M
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P95 - P95
[7] Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V)
[J]. CIRCULATION, 2003, 108 (21)
[8] Stroke prevention with the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation: Pooled analysis of the SPORTIF III and V trials
Petersen, P.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 29 - 29
[9] Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction
Christersson, C
Oldgren, J
Bylock, A
Wallentin, L
Siegbahn, A
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (10) : 2245 - 2253
[10] Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease
Douros, Antonios
Cui, Ying
Platt, Robert W.
Filion, Kristian B.
Sebastiani, Giada
Renoux, Christel
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (03) : 994 - 1009

← 1 2 3 4 5 →